HCA Healthcare’s second quarter results reflected steady demand for hospital services and a favorable payer mix, with management attributing performance to growth in high-acuity service lines like cardiac and neonatal care, as well as operational efficiencies across its local health networks. CEO Sam Hazen noted, “We had 14 out of 15 divisions that grew their admissions, and our cardiac procedure volume was up 5%.” The company also benefited from improved labor cost controls and a stable operating environment, supporting consistent margins and cash flow generation despite modest softness in Medicaid and self-pay admissions.
Is now the time to buy HCA? Find out in our full research report (it’s free).
HCA Healthcare (HCA) Q2 CY2025 Highlights:
- Revenue: $18.61 billion vs analyst estimates of $18.47 billion (6.4% year-on-year growth, 0.7% beat)
- Adjusted EPS: $6.84 vs analyst estimates of $6.32 (8.2% beat)
- Adjusted EBITDA: $3.85 billion vs analyst estimates of $3.71 billion (20.7% margin, 3.9% beat)
- The company slightly lifted its revenue guidance for the full year to $75 billion at the midpoint from $74.3 billion
- Adjusted EPS guidance for the full year is $26.25 at the midpoint, beating analyst estimates by 3.2%
- EBITDA guidance for the full year is $15 billion at the midpoint, above analyst estimates of $14.85 billion
- Operating Margin: 16%, in line with the same quarter last year
- Same-Store Sales rose 1.8% year on year (5.8% in the same quarter last year)
- Market Capitalization: $91.33 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From HCA Healthcare’s Q2 Earnings Call
- Albert J. William Rice (UBS): Asked how much of the guidance increase was due to supplemental payments and for commentary on volume trends. CFO Michael Marks clarified that about half of the increase was from supplemental programs and noted Medicaid and self-pay volumes were below expectations, but commercial and Medicare remained solid.
- Ann Kathleen Hynes (Mizuho): Inquired about details and expected impact of resiliency programs. Marks responded that benchmarking, automation, and field-level operational improvements are in progress, with more information to come when 2026 guidance is provided.
- Benjamin Hendrix (RBC Capital Markets): Asked about commercial volume trends and whether waning consumer confidence is a factor. Marks said managed care admissions met expectations and CEO Hazen noted that healthcare demand remains largely inelastic, with little evidence of consumer confidence affecting volumes.
- Matthew Dale Gillmor (KeyBanc): Requested insight into underperforming markets and corrective actions. Hazen explained that two divisions underperformed due to competitive and service mix issues, but leadership expects recovery in the second half of the year.
- Raj Kumar (Stephens): Queried the status of the $600–800 million cost savings target from prior resiliency initiatives. Marks said benchmarking and digital transformation efforts have accelerated, with a full update to come in the next guidance cycle.
Catalysts in Upcoming Quarters
In tracking HCA Healthcare’s progress, our analysts will focus on (1) execution and timing of supplemental Medicaid payments, especially the rollout of the Tennessee program, (2) the implementation and measurable impact of cost reduction and digital transformation initiatives, and (3) any clarity on federal policy actions affecting Medicaid and insurance exchanges. The development of HCA’s resiliency program and recovery in previously underperforming divisions will also be important to watch.
HCA Healthcare currently trades at $390.31, up from $341.29 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
